Skip to content
Pinacidil
Pindac (pinacidil) is a small molecule pharmaceutical. Pinacidil was first approved as Pindac on 1989-12-28. It is used to treat hypertension in the USA. It is known to target ATP-sensitive inward rectifier potassium channel 11 and ATP-sensitive inward rectifier potassium channel 8.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pinacidil
Tradename
Company
Number
Date
Products
PINDACLEO PharmaN-019456 DISCN1989-12-28
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DG: Guanine derivatives acting on arteriolar smooth muscle
— C02DG01: Pinacidil
— C02L: Antihypertensives and diuretics in combination
— C02LX: Other antihypertensives and diuretics in atc
— C02LX01: Pinacidil and diuretics
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L2033825443
Oral lichen planusD017676—211—4
EczemaD004485HP_0000964L30.9———1—1
VitiligoD014820EFO_0004208L80———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary diseaseD003327——2——2
Perioral dermatitisD019557EFO_1001305L71.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ExanthemaD005076R21—1———1
PrurigoD011536L28.2—1———1
Seborrheic dermatitisD012628L21—1———1
Lichen sclerosus et atrophicusD018459L90.0—1———1
Netherton syndromeD05677011———1
Keratoconjunctivitis siccaD007638EFO_1000906—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Discoid lupus erythematosusD008179L93.0————22
Cutaneous lupus erythematosusD008178EFO_0003834L93.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePINACIDIL
INNpinacidil
Description
1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine is a member of pyridines.
Classification
Small molecule
Drug classvasodilators (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C.O
Identifiers
PDB—
CAS-ID60560-33-0
RxCUI—
ChEMBL IDCHEMBL1200338
ChEBI ID34923
PubChem CID4826
DrugBankDB06762
UNII IDBB4UGO5K0D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNJ11
KCNJ11
KCNJ8
KCNJ8
Organism
Homo sapiens
Gene name
KCNJ11
Gene synonyms
NCBI Gene ID
3767
Protein name
ATP-sensitive inward rectifier potassium channel 11
Protein synonyms
beta-cell inward rectifier subunit, IKATP, Inward rectifier K(+) channel Kir6.2, inwardly rectifing potassium channel subfamily J member 11, inwardly rectifying potassium channel KIR6.2, inwardly-rectifying potassium channel subfamily J member 11, potassium channel inwardly rectifing subfamily J member 11, Potassium channel, inwardly rectifying subfamily J member 11, potassium voltage-gated channel subfamily J member 11
Uniprot ID
Q8IW96
Mouse ortholog
Kcnj11 (16514)
ATP-sensitive inward rectifier potassium channel 11 (Q9QX21)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,686 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,465 adverse events reported
View more details